ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Samsung venture bringing breast cancer biosimilar to Europe

Samsung Bioepis becomes first to win EU approval for alternative to blockbuster drug

Samsung Bioepis is now approved to sell four biosimilar drugs in Europe.

SEOUL -- Samsung Bioepis will soon debut a biosimilar alternative to a top-selling breast cancer drug in Europe, marking a step forward for the Samsung conglomerate's pharmaceutical operations.

Produced by biological processes, biosimilars have nearly the same effect as existing pharmaceuticals but unlike generics, are not exact copies.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more